Clinical trials: Glomerular Filtration Rate
Glomerular Filtration Rate, Heart Failure
MediBeacon® Transdermal GFR System for the Evaluation of Kidney Function in Adults With Heart Failure
The goal of this clinical trial is to evaluate the accuracy and feasibility of transdermal glomerular filtration rate (tGFR) assessment using relmapirazin (Lumitrace) and the MediBeacon tGFR system compared to plasma clearance…
- Trial name
- NCT07349797
- Testing
- Lumitrace, MediBeacon Transdermal Glomerular Filtration Rate Measurement System (tGFR), Iohexol
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- MediBeacon
Obesity, Metabolic Syndrome
Prospective Cohort Study of the Effect of Bariatric/Metabolic Surgery on Morbid Obesity Patients With Metabolic Syndrome
The purpose of this study is to determine the change in kidney function and blood pressure after gastric bypass versus conventional medical therapy in morbid obesity.
- Trial name
- NCT02271568
- Testing
- Bariatric surgery, Intensive medical therapy
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- Hanyang University
Kidney Dysfunction, Heart Transplantation
Shift to Everolimus (RAD) Kidney Sparing Study
The purpose of this study is to verify if the combination of Everolimus with a very low dose of cyclosporine is more effective than the combination of mycophenolate mofetil with low-dose of cyclosporine in reducing the…
- Trial name
- NCT00420537
- Testing
- cyclosporine, Mycophenolate mofetil, Everolimus
- Where
- Italy
- Volunteers
- 34 people
- Sponsor
- University of Bologna
Heart Failure, Chronic Kidney Diseases
DKK3 for Prognosis and Monitoring of GFR Decline in Heart Failure
The individual course of chronic kidney disease (CKD) may vary, and improved methods for identifying which patients will experience estimated glomerular filtration rate (eGFR) decline are needed.
- Trial name
- NCT04111094
- Testing
- No intervention
- Where
- Germany
- Volunteers
- 290 people
- Sponsor
- University of Giessen
Renal Artery Obstruction, Stents
Compare Effects of Intensive Versus Conventional Lipid-lowering Therapy in Patients With Severe Atherosclerotic Renal Artery Stenosis Undergoing Stent Placement
Although expert consensuses recommend the use of statins in the treatment of atherosclerotic renal artery stenosis, in patients with severe atherosclerotic renal artery stenosis undergoing stent placement, the related…
- Conditions
- Renal Artery Obstruction, Stents, Lipids, Glomerular Filtration Rate
- Trial name
- NCT03521700
- Testing
- Rosuvastatin
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Chinese Academy of Medical Sciences, Fuwai Hospital
Iohexol, Pharmacokinetics
Renal Function Assessment in Critically Ill Children
Identification of renal dysfunction in critically ill children is often delayed due to lack of accurate methods for evaluation of glomerular filtration rate (GFR).
- Conditions
- Iohexol, Pharmacokinetics, Renal Function, Critically Ill Children
- Trial name
- IOHEXOL (NCT05179564)
- Testing
- iohexol administration, iohexol blood sampling
- Where
- Belgium
- Volunteers
- 100 people
- Sponsor
- University Hospital, Ghent
Transplant; Failure, Kidney, Renal Disease, End Stage
Oral Paricalcitol in Kidney Transplant Recipients
This study is being done to find out whether patients who receive a kidney transplant can benefit from taking the medication paricalcitol (trade name Zemplar®) as compared to kidney transplant recipients not taking this…
- Conditions
- Transplant; Failure, Kidney, Renal Disease, End Stage, Hyperparathyroidism, Secondary
- Trial name
- NCT00587158
- Testing
- Paricalcitol, Corticosteroid Avoidance Immune Suppression Protocol
- Where
- 2 sites in United States
- Volunteers
- 100 people
- Sponsor
- Mayo Clinic
Lupus Nephritis
Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V
The overall purpose of this two-part study is to evaluate the efficacy, safety and tolerability of iptacopan (LNP023) in addition to standard of care treatment.
- Trial name
- NCT05268289
- Testing
- Iptacopan (part 1), Iptacopan (part 2)
- Where
- 74 sites in United States, Argentina and 17 more
- Volunteers
- 81 people
- Sponsor
- Novartis Pharmaceuticals